Interventions in the House of Commons
 
 
 
RSS feed based on search criteria Export search results - CSV (plain text) Export search results - XML
Add search criteria
View Francis Scarpaleggia Profile
Lib. (QC)
View Francis Scarpaleggia Profile
2019-06-19 21:33 [p.29484]
Mr. Speaker, sometimes I wonder if the NDP would like no trade agreements, without regard for the consequences.
The hon. member, who gave a very eloquent speech, described the USMCA as “something on trade”, forgetting that it was an arduous negotiation that was carried out wonderfully by the Minister of Foreign Affairs and the government.
However, I would like to go back to the extension of pharmaceutical patents. I would accept the hon. member's point if we were talking about traditional drugs. In the case of traditional drugs, generics are ready to pounce the moment a patent is lifted, but we are talking about biologics and biosimilars, which are the generic versions of biologics.
All experts agree that the barriers to entry into the biosimilars market are extremely high, because we are dealing with extremely complex drugs. The notion that patent extensions may be having an impact really is moot, because the barriers to entry will prevent biosimilars from quickly entering the market when there are no patent protections.
It is not really a proper parallel to make. It is alarming Canadians for no reason. Could the member comment on that?
Result: 1 - 1 of 1